

# Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: The METS-Microbiome Study

Jack Gilbert (✉ [gilbertjack@gmail.com](mailto:gilbertjack@gmail.com))

University of California San Diego <https://orcid.org/0000-0001-7920-7001>

**Gertrude Ecklu-Mensah**

University of California-San Diego <https://orcid.org/0000-0003-1770-3071>

**Maria Gjerstad Maseng**

University of Oslo

**Sonya Donato**

University of California San Diego

**Candice Coo-Kang**

Loyola University

**Lara Dugas**

Loyola University Chicago <https://orcid.org/0000-0002-0692-8585>

**Pascal Bovet**

University Center for Primary Care and Public Health

**Kweku Bedu-Addo**

Kwame Nkrumah University of Science and Technology

**Jacob Plange-Rhule**

Kwame Nkrumah University of Science and Technology

**Terrence Forrester**

University of West Indies <https://orcid.org/0000-0001-7976-8669>

**Estelle Lambert**

University of Cape Town

**Dale Rae**

University of Cape Town

**Amy Luke**

Loyola University School of Medicine <https://orcid.org/0000-0001-8484-9439>

**Brian Layden**

University of Illinois at Chicago

**Stephen O'Keefe**

**Keywords:**

**Posted Date:** April 13th, 2023

**DOI:** <https://doi.org/10.21203/rs.3.rs-2791107/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

The relationship between gut microbiota, short chain fatty acid (SCFA) metabolism, and obesity is still not well understood. Here we investigated these associations in a large (n=1904) African origin cohort from Ghana, South Africa, Jamaica, Seychelles, and the US. Fecal microbiota diversity and SCFA concentration were greatest in Ghanaians, and lowest in the US population, representing the lowest and highest end of the epidemiologic transition spectrum, respectively. Obesity was significantly associated with a reduction in SCFA concentration, microbial diversity and SCFA synthesizing bacteria. Country of origin could be accurately predicted from the fecal microbiota (AUC=0.97), while the predictive accuracy for obesity was inversely correlated to the epidemiological transition, being greatest in Ghana (AUC = 0.57). The findings suggest that the microbiota differences between obesity and non-obesity may be larger in low-to-middle-income countries compared to high-income countries. Further investigation is needed to determine the factors driving this association.

## Introduction

Obesity, which affects more than 600 million adults worldwide (“Obesity and Overweight” n.d.), over a third of Americans (Hales et al. 2020), and accounts for over 60% of deaths related to high body mass index (BMI) (Tseng and Wu 2019), remains an ongoing global health epidemic that continues to worsen at an alarming rate. A major driver of obesity is the adoption of a western lifestyle, which is characterized by excessive consumption of ultra-processed foods. Obesity is a major risk factor for type 2 diabetes, and according to the most recent National Diabetes Statistics Report almost 13% of the adult US population now have diabetes. Not only do 49.6% of adult African Americans present with obesity but over 17% of them now have diabetes, and are 1.5 times as likely to present with type 2 diabetes compared to whites (“National Diabetes Statistics Report” 2022). Populations of African origin outside of the US are experiencing similar fates, as the prevalence of obesity among adults living in Sub-Saharan Africa is greater than 13%, and higher than the global obesity prevalence for adults (Agyemang et al. 2016). This has been accompanied by dramatic increases in the prevalence of non-communicable diseases such as type two diabetes and hypertension among people of African origin (Roth et al. 2020; Gouda et al. 2019). Therefore, disrupting the rapidly expanding obesity epidemic, particularly among African origin populations is critical to controlling the cardiometabolic disorder epidemic (Geng et al. 2022). However, successfully managing and treating obesity and its comorbidities, and specifically maintaining weight loss long-term, is particularly challenging due to an incomplete understanding of the heterogeneous and complex etiopathology, as well as additional challenges facing populations experiencing rapid urbanization (Nordmo, Danielsen, and Nordmo 2020; Geng et al. 2022; Barone et al. 2022). The epidemiologic transition is a model able to capture these shifts in dietary and rural to urban movements and is characterized by diets that are high in ultra-processed foods with a significant loss in fiber, as evidenced in the US, where less than 50% of the population meet dietary fiber recommendations (Dahl and Stewart 2015).

Gut microbial ecology and metabolism play pivotal roles in the onset and progression of obesity and its related metabolic disorders (Ley 2010). Obese and lean individuals have reported differences in the composition and functional potential of the gut microbiome, with an overall reduction in species diversity in the obese gut (Dugas, Bernabé, et al. 2018; Greenblum, Turnbaugh, and Borenstein 2012; Jumpertz et al. 2011; Ley et al. 2006; Turnbaugh et al. 2009; Le Chatelier et al. 2013), additionally, fecal microbiota transfer from obese donors to mouse models can recapitulate the obese phenotype (Turnbaugh et al. 2006, 2008; Ridaura et al. 2013). Further, fecal microbiota transplant from healthy donors into patients with obese and metabolic syndrome has been shown to improve markers of metabolic health in the recipients (Vrieze et al. 2012). While these studies suggest that modification of microbial ecology may offer new options for the treatment and prevention of obesity, the mechanism that drives the microbiota-obesity relationship is not fully understood. The microbiota may facilitate greater energy exploitation from food, and storage capacity by the host (Turnbaugh et al. 2006; DiBaise et al. 2008), influencing adipose tissue composition and fat mass gain, as well as providing chronic low-grade inflammation and insulin resistance (Cani and Delzenne 2009; J. L. Sonnenburg and Bäckhed 2016).

Among the numerous microbial metabolites modulating obesity, there is an ever-growing interest in the role of short-chain fatty acids (SCFAs), which includes butyrate, acetate, and propionate as potential biomarkers for metabolic health as well as therapeutic targets. SCFAs derive primarily from microbial fermentation of non-digestible dietary fiber in the colon. They have many effects on host metabolism including serving as an energy source for host colonocytes, used as precursors for the biosynthesis of cholesterol, lipids, proteins and regulating gut barrier activities (Dalile et al. 2019; Koh et al. 2016; van der Hee and Wells 2021). Human and animal studies demonstrate a protective role of SCFAs in obesity and metabolic disease. In experimental animal models, SCFA supplementation reduces body weight, improves insulin sensitivity, and reduces obesity-associated inflammation (Vinolo et al. 2011; Gao et al. 2009; Henagan et al. 2015; Lu et al. 2016; Bonomo et al. 2020). In humans, increased gut production of butyrate correlates with improved insulin response after an oral glucose-tolerance test (Sanna et al. 2019). Although increased SCFA levels are generally observed as positive for health (Valdes et al. 2018), other studies have suggested that overproduction may promote obesity, possibly resulting from greater energy accumulation (Schwiertz et al. 2010; Rahat-Rozenbloom et al. 2014; Teixeira et al. 2013). Indeed, a previous study observed greater fecal SCFA concentrations to be linked with obesity, increased gut permeability, metabolic dysregulation, and hypertension in a human cohort (de la Cuesta-Zuluaga, Mueller, et al. 2018).

The conflicting obesity role of SCFAs identified by existing studies may result from the variation in the gut microbiota, which is shaped by lifestyle and diet. Adequately powered studies in well-characterized populations may permit more rigorous assessments of individual differences. Prior comparative epidemiological studies have broadly focused on either contrasting the gut microbiota of extremely different populations, such as the traditional hunter-gatherers and urban-westernized countries, or ethnically homogenous populations (Pasolli et al. 2019; He et al. 2018; Peters et al. 2018; Zhernakova et al. 2016). Demographic factors represent one of the largest contributors to the individualized nature of the gut microbiome (Falony et al. 2016; Zhernakova et al. 2016; Yatsunenکو et al. 2012). The five diverse,

well-defined cohorts from the Modeling the Epidemiologic Transition Study (METS) offers a unique opportunity to examine the issues since they are more representative of most of the world's population. METS has longitudinally followed an international cohort of approximately 2,500 African origin adults spanning the epidemiologic transition from Ghana, South Africa, Jamaica, Seychelles, and the US since 2010 to investigate differences in health outcomes utilizing the framework of the epidemiologic transition. Pioneering microbiome studies from the METS cohorts reveal that cardiometabolic risk factors including obesity is significantly associated with reduced microbial diversity, and the enrichment of specific taxa and predicted functional traits in a geographic-specific manner (Dugas, Bernabé, et al. 2018; Fei et al. 2019). While yielding valuable descriptions of the connections between the gut microbiota ecology and disease, particularly obesity, as well as pioneering the efforts of microbiome studies of populations of African origin on different stages of the ongoing nutritional epidemiologic transitions, these studies, however, have applied small sample size (N=100 to N=655), and also did not utilize all the countries in the METS cohort. Thus, uncertainties remain as to the precise interpretation of the microbiome-obesity associations, which hampers further progress towards diagnostic and clinical applications.

Our new study METS-Microbiome investigated associations between the gut microbiota composition and functional patterns, concentrations of fecal SCFAs and obesity in a large (N= 1,904) adult population cohort of African origin, comprised of Ghana, South Africa, Jamaica, Seychelles, and the US spanning the epidemiologic transition (Dugas, Lie, et al. 2018; Luke et al. 2011). The central hypothesis is that shifts towards the highest end of the epidemiologic transition spectrum is associated with alterations in microbiota diversity and community composition, reductions in levels of fecal SCFAs and obesity.

## Results

*Obesity differs significantly across the epidemiological transition.* From 2018-2019, the METS-Microbiome study recruited 2,085 participants (~60% women) ages 35-55 years old from five different sites (Ghana, South Africa, Jamaica, Seychelles, and US). Of these participants, 1,249 have been followed on a yearly basis since 2010 under the parent METS study. Data from 1,867 participants with complete data sets were used in this analysis. Overall mean age was  $42.5 \pm 8.0$  years (Table 1). Mean fasted blood glucose was  $105.2 \pm 39.4$  mg/dL, mean systolic blood pressure was  $123.4 \pm 18.1$  mm Hg and mean diastolic blood pressure was  $77.2 \pm 13.1$  (Table 1). When compared to the high-income countries (Jamaica, Seychelles, and US), both women and men from the lower- and middle-income countries (Ghana and South Africa) had significantly lower BMI, fasted blood glucose and blood pressure (systolic and diastolic). Mean BMI was lowest in the South African men ( $22.3 \text{ kg/m}^2 \pm 4.1$ ) and highest in US women ( $36.3 \text{ kg/m}^2 \pm 8.8$ ). When compared to the US, all sites had significantly lower prevalence of obesity ( $p < 0.001$  for all sites except for Seychelles:  $p = 0.02$ ). Prevalence of hypertension was lowest in Ghanaian men (33.1%) and highest in US men (72.7%). Prevalence of diabetes was lowest in South African women and men (3.5% for women and men) and highest for Seychellois men (22.8%). When compared to the US, prevalence of hypertension and diabetes was significantly lower in countries at the lower end of the spectrum of HDI (i.e., Ghana and South Africa) when compared to the US ( $p < 0.001$ ).

*Microbial community composition and predicted metabolic potential differs significantly between countries and correlates with obesity.* Following the removal of samples that had fewer than 6,000 reads and features less than ten reads in the entire dataset, a total of 433,364,873 16S rRNA gene sequences were generated from the 1,873 fecal samples which were clustered into 13,254 ASVs. Country of origin describes most of the variation in microbial diversity and composition, with significant differences in both alpha and beta diversity. Although there were major variations in alpha diversity between countries and large degree of inter-individual variation within countries, Ghana showed significantly greater diversity for all the alpha diversity metrics (Observed ASVs, Shannon Diversity and Faith's phylogenetic diversity) when compared to all other countries. The Seychelles and US had the lowest alpha diversity (Fig. 1). The stool microbiota alpha diversity of non-obese individuals was significantly greater when compared with that of obese individuals (Fig. 1). Beta diversity was also significantly different between countries (Fig. 1, Supplementary Tables 2 & 3; principal coordinate analysis, weighted UniFrac distance; F-statistic =58.67;  $p < 0.001$ ; unweighted UniFrac distance;  $F = 39.87$ ;  $p < 0.001$ ) and obese group (weighted UniFrac distance; F-statistic =2.39;  $p = 0.031$ ; unweighted UniFrac distance;  $F = 6.06$ ;  $p < 0.001$ ).

Next, we compared fecal microbiota diversity between obese individuals with their non-obese counterparts within each country independently. Greater alpha diversity was detected in non-obese subjects in the Ghanaian (Observed ASVs, Faith PD;  $p < 0.05$ ) and South African cohorts (Observed ASVs;  $p < 0.05$ ) only (Supplementary Table 1). Similarly, significant differences in beta diversity between obese and non-obese microbiota were observed in Ghana (Unweighted UniFrac;  $p < 0.05$ ), South Africa (Unweighted UniFrac;  $p < 0.05$ ) and US (Weighted UniFrac;  $p < 0.05$ ) data sets (Supplementary Tables 2 & 3). These results suggest that the beta diversity differences observed in the Ghanaian and South African participants may partly be due to the presence of more abundant fecal microbiota taxa in the fecal samples whereas among the US participants, the differences may be related to the abundance of rare taxa. Collectively, these observations suggest that country is a major driver of the variance in gut microbiota diversity and composition among participants with or without obesity with marked contributions from Ghana and South Africa and modest contribution from the US in the overall cohort.

We also examined whether country of origin or obesity relates to the presence of specific microbial genera frequently used to stratify humans into enterotypes (Arumugam et al. 2011). As expected, large differences in enterotype between the countries were observed. The *Prevotella* enterotype (P-type) was enriched on the African continent, with 81% and 62% in Ghanaians and South Africans respectively while *Bacteroides* enterotype (B-type) was dominant in the US (75%), Jamaican cohorts (68%), and comparable proportions of both enterotypes among individuals from Seychelles. Further, obese individuals displayed a greater abundance of B-type whereas a higher proportion of the P-type associated with the non-obese group (Supplementary Table 4). Consistent with this observation, the abundance of B-type correlated with higher BMI ( $p = 0.004$ ) than P-type. Significantly greater diversity and increased levels of total SCFA were observed in participants in the P-type (Supplementary Table 4). The relative abundance of shared and unique features between the different countries illustrated by the Venn diagram showed that Ghana carries the largest proportion of unique taxa than the other countries, and US the lowest (Fig. 1).

*Microbial taxa differ significantly between countries and between lean and obese individuals.* In comparison with the US, South African fecal microbiota had a significantly greater proportion of *Clostridium*, *Olsenella*, Bacilli and *Mogibacterium*; Jamaican samples had a significantly greater proportion of Bacilli, *Bacteroides*, Clostridia, *Dialister*, Enterobacteriaceae, and Oscillospiraceae; Seychelles samples had a significantly greater proportion of *Clostridium*, *Olsenella* and *Haemophilus*; and Ghanaian samples had a significantly greater proportion of *Clostridium*, *Prevotella*, *Weisella*, Enterobacteriaceae and Butyricocccaceae. The US samples had a significantly greater proportion of *Aldercreutzia*, *Anaerostipes*, *Clostridium*, *Eggerthella*, *Eisenbergiella*, Ruminococcaceae and *Sellimonas* compared to the 4 countries (Fig. 2 and Supplementary Fig. 1).

When adjusted for country, age, and sex ( $p < 0.05$ ; false discovery rate (fdr)-corrected), 38 Amplicon Sequence Variants (ASVs) were significantly different between obese and non-obese groups. The obese group was characterized by an increased proportion of *Allisonella*, *Dialister*, *Oribacterium*, *Mitsuokella*, and *Lachnospira*, whereas non-obese microbiota had a significantly greater proportion of *Alistipes*, *Bacteroides*, *Clostridium*, *Parabacteroides*, *Christensenella*, *Oscillospira*, Ruminococcaceae (UBA1819), and Oscillospiraceae (UCG010) (Fig. 2).

*Microbial taxonomic features predict obesity overall and within each country.* Using supervised Random Forest machine learning, the predictive capacity of the gut microbiota features in stratifying individuals to country of origin, sex, or with metabolic phenotypes were assessed. The predictive performance of the model was calculated by area under the receiver operating characteristic curve (AUC) analysis, which showed a high accuracy for country of origin (AUC = 0.97), and a comparatively lower level of predictive accuracy for obese state (AUC = 0.65) (Fig. 3). Sex was predicted with AUC = 0.75, the diabetes status with AUC = 0.63, hypertensive status with AUC = 0.65 and glucose status with AUC = 0.66. Random Forest analysis was also used to identify the top 30 microbial taxonomic features that differentiate between countries and obese states. Similar to the ANCOMBC results, *Prevotella* and *Streptococcus* were at a greater proportion in the microbiota of Ghanaian and non-obese individuals, whereas *Mogibacterium* was at a greater proportion in the South African cohort. A greater proportion of *Megasphaera* was associated with the Jamaican cohort, while a greater proportion of Ruminococcaceae was observed in the American microbiota. *Weisella*, which was identified as having a significantly greater proportion in the Ghanaian cohort using ANCOMBC, was observed to be a discriminatory feature for Seychelles microbiota using Random Forest (Supplementary Fig. 2).

Similarly, the predictive capacity of the gut microbiota features in stratifying individuals by obese state was assessed at each of the five study sites. The predictive performance of the model was calculated by AUC analysis, which showed a moderate accuracy for obese state for all sites, namely, Ghana (AUC = 0.57), South Africa (AUC = 0.52), Jamaica (AUC = 0.48), Seychelles (AUC = 0.43) and US (AUC = 0.52) (Supplementary Fig. 3).

*Predicted genetic metabolic potential differs by country and obesity status.* The predicted potential microbial functional traits resulting from the compositional differences in microbial taxa between

countries and obese state were assessed. PICRUSt2 predicted a total of 372 MetaCyc functional pathways. ANCOM-BC analysis adjusted for sex, age and BMI identified 67 pathways ( $p < 0.05$ ; false discovery rate (fdr)-corrected),  $LFC > 1.4$ ) that accounted for discriminative features between the 4 different countries with the US (Supplementary Fig. 4). In comparison with US, MetaCyc pathways differentially increased in Ghana and Jamaica include methylgallate degradation, norspermidine biosynthesis (PWY-6562), gallate degradation I pathway, gallate degradation II pathway, histamine degradation (PWY-6185), and toluene degradation III (via p-cresol) (PWY-5181). South African samples had a greater proportion of L-glutamate degradation VIII (to propanoate) (PWY-5088), isopropanol biosynthesis (PWY-6876), creatinine degradation (PWY-4722), adenosyl cobalamin biosynthesis (anaerobic) (PWY-5507), respiration I (cytochrome c) (PWY-3781). MetaCyc pathways linked to norspermidine biosynthesis (PWY-6562), mycothiol biosynthesis (PWY1G-0), were at a greater proportion in the Seychelles samples, whereas reductive acetyl coenzyme A (CODH-PWY), and chorismate biosynthesis II (PWY-6165) were depleted in the US samples. ANCOM-BC analysis adjusted for site, sex and age identified 24 predicted pathways that differentiated between obese and non-obese individuals (Supplementary Fig. 4). Notably, the microbiota of non-obese individuals had a greater proportion of predicted pathways including the TCA cycle, amino acid metabolism (P162-PWY, PWY-5154, PWY-5345), ubiquinol biosynthesis-related pathways (PWY-5855, PWY-5856, PWY-5857, PWY-6708, UBISYN-PWY), cell structure biosynthesis and nucleic acid processing (PWY0 845, PYRIDOXSYN-PWY).

Next, KEGG orthology (KO) involved in pathways related to butanoate (butyrate) metabolism and LPS biosynthesis were investigated. Predicted genes involved in butyrate biosynthesis pathways showed that enoyl-CoA hydratase enzymes (K01825, K01782, K01692), lysine, glutarate /succinate enzymes (K07250, K00135, K00247), glutarate/Acetyl CoA enzymes (K00175, K00174, K00242, K00241 K01040, K01039) were differentially abundant in participants from Ghana, South Africa, Jamaica, and Seychelles in comparison to the US cohort. The relative abundance of succinic semialdehyde reductase (K18122) was significantly increased only in South Africa, Jamaica, and Seychelles population. Further, predicted genes proportionally abundant only in specific countries were observed. For instance, succinate semialdehyde dehydrogenase (K18119) was enriched only in the Ghanaian cohort, 4-hydroxybutyrate CoA-transferase (K18122) enriched among South African participants and lysine/glutarate/succinate enzyme (K14268) differentially abundant within the Seychelles population. The relative abundance of predicted genes encoded for enzymes such as maleate isomerase (K10799), 3-oxoacid CoA-transferase (K01027) and pyruvate/acetyl CoA (K00171, K00172, K00169) were greater in the US participants compared with participants from the 4 countries (Supplementary Fig. 5). The non-obese exhibited a significantly greater abundance of genes that catalyze the production of butyrate via the fermentation of pyruvate or branched amino-acids such as enoyl-CoA hydratase enzyme (K0182), Leucine/Acetyl CoA enzyme (K01640) and pyruvate/acetyl CoA enzyme (K00171, K00172, K00169, K1907) by contrast obese individuals were differentially enriched for succinyl-CoA:acetate CoA-transferase (K18118) (Supplementary Fig. 5). All analyses were adjusted for country, sex, BMI and age (fdr-corrected  $p < 0.05$ ).

Several gut microbial predicted genes involved in LPS biosynthesis differentially enriched among the countries ( $p < 0.05$ ; false discovery rate (fdr)-corrected) were identified. In particular, the relative



abundance of specific LPS genes (K02560, K12973, K02849, K12979, K12975, K12974) were significantly enriched in Ghana, South Africa, Jamaica, and Seychelles when compared with US. Higher proportions of LPS genes including K12981, K12976, K09953, K03280 were significantly increased in Seychelles samples in comparison with US samples and also significantly increased in the US cohorts in comparison with participants from Ghana, South Africa, and Seychelles. US samples had a greater proportion of the following genes (K15669, K09778, K07264, K03273, K03271) in comparison with the other 4 countries (Supplementary Fig. 6). Non-obese individuals had a greater abundance of predicted genes encoding LPS biosynthesis (K02841, K02843, K03271, K03273, K19353, K02850) whereas only 1 LPS gene (K02841) differentially elevated in the non-obese group (Supplementary Fig. 6). All analyses were adjusted for country, sex, BMI and age (fdr-corrected  $p < 0.05$ ).

*Microbial community composition and taxonomy correlate with observed fecal SCFA concentrations.* All countries had significantly higher weight-adjusted fecal total SCFA levels when compared to the US participants ( $p < 0.001$ ), with Ghanaians having the highest weight-adjusted fecal total SCFA levels (Supplementary Table 5). When compared to their obese counterparts, non-obese participants had significantly higher weight-adjusted fecal total and individual SCFA levels (Supplementary Table 6). Total SCFA levels displayed weak, but significantly positive correlation with Shannon diversity ( $r = 0.074$ ). A similar trend was observed in the different individual SCFAs, namely valerate ( $r = 0.19$ ), butyrate ( $r = 0.12$ ), propionate ( $r = 0.073$ ) and acetate ( $r = 0.058$ ) (Fig. 4). Observed ASVs were not significantly correlated with total SCFAs ( $p > 0.05$ ). Levels of acetate, butyrate and propionate exhibited strong significant correlations with total SCFA, whereas valerate levels significantly correlated negatively ( $r = -0.09$ ) with total SCFAs. Next, we assessed if levels of total SCFAs could be predicted by a mixed model. Country explained 45.7% of the variation in SCFAs. No significant effect was explained either by obesity or Shannon diversity.

To explore the connection between SCFAs with gut microbiota, Spearman correlations between taxa that were proportionally significantly different between countries and concentrations of SCFAs were determined. Valerate negatively correlated with the proportion of *Clostridium*, *Prevotella*, *Faecalibacterium*, *Roseburia* and *Streptococcus*, which were all positively correlated with acetate, propionate, and butyrate. Similarly, the proportions of Christensenellaceae, *Eubacterium*, and UCG 002 (Ruminococcaceae) were significantly positively associated with valerate, and negatively correlated with acetate, propionate, and butyrate. In addition, only a single ASV annotated to *Ruminococcus* was observed to be positively associated with all 4 SCFAs (Fig. 5). Similarly, Spearman's rank correlation coefficients were calculated between the differentially abundant ASVs identified between obese and non-obese group with concentrations of SCFAs. Broadly, the proportions of most ASVs were significantly positively associated with acetate in comparison with the other 3 SCFAs. Consistent with the correlations mentioned above, valerate negatively correlated with most ASVs that were found to be positively correlated with the three major SCFAs, acetate, propionate, and butyrate and vice versa. The relative proportions of ASVs belonging to *Allisonella*, Erysipelotrichaceae and *Libanicoccus* positively correlated with acetate, propionate, and butyrate, whereas significantly negative relationships were observed between *Parabacteroides* and *Bacteroides* abundances with the aforementioned SCFAs. Valerate showed

significantly positive associations with *Oscillospirales* and *Ruminococcaceae* abundances and significantly negative correlations with *Lachnospira* and *Eggerthella* abundances (Fig. 5).

## Discussion

By leveraging a well characterized large population-based cohort of African origin residing in geographically distinct regions of Ghana, South Africa, Jamaica, Seychelles, and the US, we examined the relationships between gut microbiota, SCFAs and adiposity. Our data revealed profound variations in gut microbiota, which are reflected in the significant changes in community composition, structure, and predicted functional pathways as a function of population obesity and geography, despite their shared ancestral background. Our data further revealed an inverse relation between fecal SCFA concentrations, microbial diversity, and obesity; importantly, the utility of the microbiota in predicting whether an individual was lean or obese was inversely correlated with the income-level of the country of origin. Overall, our findings are important for understanding the complex relationships between the gut microbiota, population lifestyle and the development of obesity, which may set the stage for defining the mechanisms through which the microbiome may shape health outcomes in populations of African origin.

As reported previously our data showed that geographic origin can modulate the composition of the gut microbiota. Our findings were also consistent with our previous METS studies (Fei et al. 2019; Dugas, Bernabé, et al. 2018) and other large scale continental cohort studies (De Filippo et al. 2010, 2017; Yatsunencko et al. 2012; Schnorr et al. 2014; Clemente et al. 2015; Rampelli et al. 2015; Gomez et al. 2016; Mancabelli et al. 2017), that report a higher bacterial diversity and composition/microbial richness in traditionally non-western groups that distinguish them from urban-industrialized individuals whose diets are low in fiber and high in saturated fats (E. D. Sonnenburg and Sonnenburg 2019; Kolodziejczyk, Zheng, and Elinav 2019). Although we observe enrichment in the relative abundance of several taxa associated with country of origin in our cohorts, we also detect a pattern where the gut microbiota of Ghanaian and South African cohort tends to share many features, while the gut microbiota of the Jamaican cohort shared many features with all 4 countries, possibly reflecting the ongoing epidemiological transitional nature of their communities represented by the overlap with western and traditionally non-western populations. Notably, traditionally non-western associated taxa including *Prevotella*, *Butyrivibrio*, *Weisella* and *Romboutsia* were enriched in participants from Ghana and South Africa, as suggested previously (Mancabelli et al. 2017). Western-associated taxa such as *Bacteroides* and *Parabacteroides* were enriched in individuals from Jamaica and the US (Mancabelli et al. 2017; Kao et al. 2015), while an ASV annotated as *Olsenella* was proportionally abundant in Seychelles microbiota. *Bifidobacterium* and *Aldercreutzia* were enriched in the US cohort. *Clostridium sensu stricto* 1 was over-represented in all 4 countries in comparison with the US. We also found greater enrichment of VANISH taxa including *Butyricoccus* and *Succinivibrio* in the Ghanaian cohort, in line with individuals practicing traditional lifestyles (Pasolli et al. 2019). *Prevotella* is usually associated with plant-based diets rich in dietary fibers, while *Bacteroides* abundance broadly correlates with diets high in fat, animal protein, and sugars (Gupta, Paul, and Dutta 2017; Wu et al. 2011), which is in agreement with our enterotype analysis where a *Prevotella*-rich microbiota dominates the Ghanaian and South African gut, while a *Bacteroides*-rich

microbiota dominated in the high-income countries. As *Prevotella* synthesizes SCFAs (T. Chen et al. 2017), its depletion may lead to the observed reduction in SCFA concentrations. Our results support a potential role for geography in reinforcing variations in the gut microbiota in our study cohort despite shared origin. Geography may reflect subtle shifts in lifestyle and/or environmental exposures including heterogeneity of dietary sources, exposure to medications, socioeconomic factors, medical history, and biogeographical patterns in microbial dispersion (Asnicar et al. 2021; Pasolli et al. 2019; Costello et al. 2012; He et al. 2018).

We also inferred the metabolic capacity of the gut microbiota associated with the different countries. Several metabolic pathways linked to carrier, cofactor and vitamin biosynthesis, biosynthesis/degradation of amines, amino acids, aromatic xenobiotics, and tricarboxylic acid (TCA) cycle were differentially enriched between the different countries compared with the US. These pathways are involved in biochemical reactions that regulate several processes including energy metabolism, inflammation, epigenetic processes, and oxidative stress. Participants from Ghana and Jamaica were enriched for gallate degradation, which can result in phenolic catechin metabolites which are thought to alleviate obesity-related pathologies (Marchesi et al. 2016; Liu et al. 2021). Additionally, glutamate metabolism, which can be fermented to butyrate and propionate, was enriched in South Africans and Ghanaians compared to the US. In the Seychelles, actinobacterial mycothiol biosynthesis was upregulated, which is involved in antioxidant activity and the removal of toxic compounds from cells (Newton, Buchmeier, and Fahey 2008). We further identified an increase in SCFA synthesis pathways, e.g. acetyl coenzyme A pathway, threonine biosynthesis, and leucine degradation in the microbiomes of all four countries compared to the US. Further studies are required to evaluate the potential causal relations of these gut microbial functions with health outcomes using shotgun metagenomic sequencing.

Preclinical mouse models provided early causal links between gut microbial ecology and obesity (Ley et al. 2005; Bäckhed et al. 2007), suggesting the potential to predict obesity risk from the microbiome. However, prediction has proven difficult because results are conflicting (Finucane et al. 2014). As we observed, the bulk of evidence from prior studies show that obesity is associated with a less diverse bacterial community (Turnbaugh et al. 2009; Dugas, Bernabé, et al. 2018; Peters et al. 2018). In addition, we identified several SCFA producing bacteria that were significantly depleted in obese individuals, which may influence host energy metabolism. For example, *Oscillospira* and *Christensenella* which were statistically associated with increases SCFA concentrations and reduced obesity have previously been associated with a lean phenotype (Beaumont et al. 2016; Konikoff and Gophna 2016; Gophna, Konikoff, and Nielsen 2017; Morotomi, Nagai, and Watanabe 2012), and produce SCFAs (Konikoff and Gophna 2016; Gophna, Konikoff, and Nielsen 2017) including butyrate, which improves insulin sensitivity and reduces inflammation (M.-H. Kim et al. 2020). We also detected several butyrate producing ASVs including *Eubacterium*, *Alistipes*, *Clostridium* and *Odoribacter* to be proportionally enriched in individuals who were non-obese. We observed that obese individuals presented a greater abundance of *Lachnospira*, which does produce SCFAs, a finding also consistent with our prior study in the same population (Dugas, Bernabé, et al. 2018), and others (Lippert et al. 2017; Meehan and Beiko 2014; de la Cuesta-Zuluaga,

Corrales-Agudelo, et al. 2018). However, other studies have observed the opposite (Companys et al. 2021; Stanislowski et al. 2017).

SCFA supplementation has been documented to protect against a high-fat diet-induced obesity in mice (H. V. Lin et al. 2012; Lu et al. 2016) as well as weight gain in humans (Chambers et al. 2015). Conversely, other studies, mostly from western populations, have reported that elevated SCFA concentrations in stool can associate with obesity (Schwiertz et al. 2010; Fernandes et al. 2014; Riva et al. 2017; de la Cuesta-Zuluaga, Mueller, et al. 2018). For instance, a Colombian cohort showed associations between elevated fecal SCFA levels, central obesity, gut permeability, and hypertension (de la Cuesta-Zuluaga, Mueller, et al. 2018). One potential explanation is that obese gut microbiota may lead to less efficient SCFA absorption, hence the increased SCFA excretion (de la Cuesta-Zuluaga, Mueller, et al. 2018). However, as we found diets high in fiber correlate positively with weight loss (Hu et al. 2013; Esposito et al. 2011) and increased levels of fecal SCFAs (De Filippis et al. 2016). One explanation may be in differences lifestyle factors, including medication, activity, and pollutant exposure, which could also impact intestinal absorption in western countries. We note that fecal SCFA concentrations are not a direct measure of intestinal SCFA production, but rather reflect a net result of the difference between production and absorption (Canfora, Jocken, and Blaak 2015). Studies using stable isotopes to measure SCFA dynamics would improve interpretation of dichotomy.

While SCFAs associate with obese phenotype, another mechanism underpinning obesity is metabolic endotoxemia. An increase in Proteobacteria, which often accompanies a high fat/high sugar diet, is often associated with an increase in circulating lipopolysaccharide (LPS) and H<sub>2</sub>S, which provoke low-grade inflammation, increased intestinal permeability, and clock gene disruption in the liver, which associate with adiposity (Zhao 2013; Cani et al. 2008; Leone et al. 2015). We identified an increase in *Dialister* in obese individuals which has been associated with increased LPS production (Yang et al. 2022; Boulangé et al. 2016), obesity (Zhang et al. 2021), sleep disruption and chronic inflammation (Yan et al. 2021; Karlsson et al. 2012; Fei and Zhao 2013; Cani et al. 2007; Fei et al. 2021). Collectively, our results demonstrate that obese individuals harbor a marked inflammatory state favoring the development of obesity, and this is in concordance with the associated metabolic endotoxemia pathway linking gut bacteria to obesity.

In obese individuals, as well as SCFA metabolism, we also detected marked depletion in pathways involved in cell structure, vitamin B6, NAD, and amino acid biosynthesis. This suggests that pathways important for growth and energy homeostasis are disrupted in individuals with obesity. We also noted an enrichment of the formaldehyde assimilation I (serine pathway) pathway. Endogenous formaldehyde produced at sufficient levels has carcinogenic properties and detrimental effects on genome stability. To counteract this reactive molecule, organisms have evolved a detoxification system that converts formaldehyde to formate, a less reactive molecule that can be used for nucleotide biosynthesis (Reingruber and Pontel 2018; N. H. Chen et al. 2016). Thus, we may infer that the pattern of increased formaldehyde assimilation pathway in our data might result from a defect or diminished capacity of formaldehyde detoxification system pathway, an assumption which requires further verification. A study

reported increases in the abundance of formaldehyde assimilation pathway in a depressed group when compared with non-depressed controls (S.-Y. Kim et al. 2022). We are the first to show that the gut of obese participants is enriched in the formaldehyde assimilation pathway. Although we do not understand the mechanistic details, it is known that toxic formaldehyde is generated along with reactive oxygen species during inflammatory processes (N. H. Chen et al. 2016). Thus, an increased capacity for formaldehyde pathway may indicate a microbiome-induced increase in reactive oxygen species in the gut of obese individuals. Indeed, prior work has identified induction of oxygen stress by microbial perturbations as one of the mechanisms by which the microbiome can promote weight gain and insulin resistance (J. Qin et al. 2012). The specific alterations of the gut microbiota and the associated predicted functionality may constitute a potential avenue for the development of microbiome-based therapeutics to treat obesity and/or to promote and sustain weight loss.

*Study strengths and limitations.* While our study has several strengths including a large sample size, diverse population along an epidemiological transition gradient with a comprehensive dataset that allowed the exclusion of the potential effects of origin as well as control of potential interpersonal covariates, and use of validated and standard tools for data collection, we acknowledge some limitations as well. First, the cross-sectional nature of our study design is unable to establish temporality or identify mechanisms by which the gut microbiome may causally influence the observed associations. In that regard, we expect that prospective data from the METS cohort study will provide the basis to assess the longitudinal association between gut microbiota composition, metabolites, and obesity, and we have an ongoing study exploring the potential correlations longitudinally. The use of 16S rRNA sequencing in our analysis for inferences on microbial functional ecology inherently has its limitations for drawing conclusions on species and strain level functionality due to its low resolution. Nevertheless, our results provide insight into the relationship between obesity, gut microbiota, and metabolic pathways in individuals of African origin across different geographies, stimulating further examination of large-scale studies using multi-omic approaches with deeper taxonomic and functional resolution and animal transplantation studies to investigate potentially novel microbial strains and to explore the clinical relevance of the observed metabolic differences.

## Conclusion

Our study analyzed the relationship between gut microbiota composition, SCFA concentrations, and obesity in a cohort of African origin from different countries. Ghanaian participants had the most diverse microbiota, and the American cohort had the least. Obese individuals had different gut microbiota composition and function compared to non-obese individuals. Non-obese participants had more SCFA-producing microbes and higher total SCFA concentrations in feces. The predictive accuracy of the microbiota for obesity was greatest in low-income countries, suggesting that lifestyle traits in high-income countries may increase obesity risk even for lean individuals. Alterations in the gut microbiota and associated metabolic functions could guide the development of microbiome-based solutions to treat obesity. Further studies using multi-omic approaches are needed to confirm the identified taxonomic and metabolic signatures.

## Methods

*Study Cohort.* Since 2010, METS, and the currently funded METS-Microbiome study has longitudinally followed an international cohort of African origin adults spanning the epidemiologic transition from Ghana, South Africa, Jamaica, Seychelles, and US (Dugas, Lie, et al. 2018; Luke et al. 2011). METS utilizes the framework of the epidemiologic transition to investigate differences in health outcomes based on country of origin. The epidemiologic transition is defined using the United Nations Human Development Index (HDI) as an approximation of the epidemiologic transition. Ghana represents a lower-middle income country, South Africa represents a middle-income country, Jamaica and Seychelles represent high income countries and the US represents a very high-income country. This framework has allowed us to investigate aspects of increased Westernization throughout the world (ex. increased consumption of ultra-processed foods) are related to increased prevalence of obesity, diabetes and cardiometabolic diseases. Our data from the original METS cohort demonstrate that the epidemiologic transition has altered habitual diets in the international METS sites, and that reduced fiber intake is associated with higher metabolic risk, inflammation, and obesity across the epidemiologic transition (Mehta et al. 2021). Originally, 2,506 African origin adults (25–45 yrs), were enrolled in METS between January 2010 and December 2011 and followed on a yearly basis. In 2018, METS participants were recontacted and invited to participate in METS-Microbiome. Participants were excluded from participating in the original METS study if they self-reported an infectious disease, including HIV-positive individuals, pregnancy, breast-feeding or any condition which prevented the individual from participating in normal physical activities. METS-Microbiome was approved by the Institutional Review Board of Loyola University Chicago, IL, US; the Committee on Human Research Publication and Ethics of Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; the Research Ethics Committee of the University of Cape Town, South Africa; the Board for Ethics and Clinical Research of the University of Lausanne, Switzerland; and the Ethics Committee of the University of the West Indies, Kingston, Jamaica. All study procedures were explained to participants in their native languages, and participants provided written informed consent after being given the opportunity to ask any questions.

*Participant anthropometry, sociodemographic and biochemical measurements.* Participants completed the research visits at the established METS research clinics located in the respective communities (Luke et al. 2011). Briefly, they presented themselves at the site-specific research clinic early in the morning, following an overnight fast. The weight of the participant was measured without shoes and dressed in light clothing to the nearest 0.1 kg using a standard digital scale (Seca, SC, USA). Height was measured using a stadiometer without shoes and head held in the Frankfort plane to the nearest 0.1 cm. Waist circumference was measured to the nearest 0.1 cm at the umbilicus, while hip circumference was measured to the nearest 0.1 cm at the point of maximum extension of the buttocks. Adiposity (% body fat) was assessed using BIA (Quantum, RJL Systems, Clinton Township, MI), and study specific equations (Luke et al. 2011). Blood pressure was measured using the standard METS protocol using the Omron Automatic Digital Blood Pressure Monitor (model HEM-7471c, Omron Healthcare, Bannockburn, IL, USA), with the antecubital fossa at heart level. Participants were asked to provide a fecal sample using a standard collection kit (EasySampler stool collection kit, Alpco, NH). Fecal samples were placed within a

-80° freezer immediately upon receipt at all the sites. Participants were requested to fast from 8 pm in the evening prior to the clinic examination, during which fasting capillary glucose concentrations were determined using finger stick (Accu-check Aviva, Roche).

*Fecal Short Chain Fatty Acid quantification.* As in our previous studies (Nooromid et al. 2020; Lewandowski et al. 2021; Reiman, Layden, and Dai 2021; Barengolts et al. 2019; Navarro et al. 2018; Dugas, Bernabé, et al. 2018), fecal SCFAs were measured using LC-MC/MS at the University of Illinois-Chicago Mass Spectrometry Core using previously published methods (Moreau et al. 2003; Richardson et al. 1989). The LC-MC/MS analysis was completed on an AB Sciex Qtrap 5500 coupled to Agilent UPLC/HPLC system. All samples were analyzed by Agilent poroshell 120 EC-C18 Column, 100Å, 2.7 µm, 2.1 mm X 100 mm coupled to an Agilent UPLC system, which was operated at a flow rate of 400 µl/min. A gradient of buffer A (H<sub>2</sub>O, 0.1% Formic acid) and buffer B (Acetonitrile, 0.1% Formic acid) were applied as: 0 min, 30% of buffer B; increase buffer B to 100% in 4 min; maintain B at 100% for 5 min. The column was then equilibrated for 3 min at 30% B between the injections with the MS detection is in negative mode. The MRM transitions of all targeted compounds include the precursor ions and the signature production ion. Unit resolution is used for both analyzers Q1 and Q3. The MS parameters such as declustering potential, collision energy and collision cell exit potential are optimized in order to achieve the optimal sensitivity. SCFAs are presented as individual SCFAs (µg/g), including: butyric acid, propionic acid, acetic acid and valeric acid, as well as total SCFAs (sum of 4).

METS data showed Ghanaians consumed the greatest amount of both soluble and insoluble fiber and had the lowest percentage energy from fat (42.5% of the Ghanaian cohort, dietary fiber intake: 24.9 g ± 9.7g/day). The US has the highest proportion of energy from fat and the lowest fiber intake of the five sites (3.2% of the US cohort, dietary fiber intake: 14.2 g ± 7.1 g/day).

*DNA extraction, Amplicon Sequencing.* Fecal samples were shipped on dry ice to the microbiome core sequencing facility, University of California, San Diego for 16S rRNA gene processing. Fecal samples were randomly sorted, transferred to 96-well extraction plates and DNA was extracted using MagAttract Power Microbiome kit. Blank controls and mock controls (ZymoBiomics) were included per extraction plate, which were carried through all downstream processing steps. Extracted DNA was used for amplification of the V4 region of the 16S rRNA gene with 515F-806R region-specific primers according to the Earth Microbiome Project (Thompson et al. 2017; Walters et al. 2016). Purified amplicon libraries were sequenced on the Illumina NovaSeq platform to produce 150 bp forward and reverse reads through the IGM Genomics Center, University of California San Diego. Full DNA extraction, amplification, quantification, and sequencing protocols and standards are available at <http://www.earthmicrobiome.org/protocols-and-standards>; (Thompson et al. 2017).

*Bioinformatic analysis.* The generated raw sequence data were uploaded and processed in Qiita (Gonzalez et al. 2018) (Qiita ID 13512) an open-source, web-enabled microbiome analysis platform. Sequences were demultiplexed, quality filtered, trimmed, erroneous sequences were removed, and amplicon sequence variants (ASVs) were defined using Deblur (Amir et al. 2017). The deblur ASV table

was exported to Qiime2 (Bolyen et al. 2019; Bokulich et al. 2018) and representative sequences of the ASVs were inserted into the Greengenes 13.8 99% identity tree with SATé-enabled phylogenetic placement (SEPP) using q2-fragment-insertion (Bolyen et al. 2019; Mirarab, Nguyen, and Warnow 2012) to generate an insertion tree for diversity computation. Additionally, the deblur ASV table was assigned taxonomic classification using the Qiime2 feature-classifier, with Naive Bayes classifiers trained on the SILVA database (version 138; (McLaren 2020)). A total of 463,258,036 reads, 154,952 ASVs and 1902 samples were obtained from the deblur table. The resulting ASV count table, taxonomy data, insertion tree, and sample metadata were exported and merged into a phyloseq (McMurdie and Holmes 2013) object in R (R Foundation for Statistical Computing, Vienna, Austria) for downstream analysis. Features with less than ten reads in the entire dataset and samples with fewer than 6,000 reads were removed from the phyloseq object. In addition, mitochondrial and chloroplast-derived sequences, non-bacterial sequences, as well as ASVs that were unassigned at phylum level were filtered prior to analyses. There were 433,364,873 reads and 13254 ASVs in the remaining 1873 fecal samples in the phyloseq object. The remaining samples after filtering were rarefied to a depth of 6,000 reads to avoid sequencing bias, before generating alpha diversity measures, leaving 9917 ASVs across 1873 samples.

*Diversity and differential proportional analyses:* Alpha diversity measures based on Observed Amplicon Sequence Variants (ASVs), Faith's Phylogenetic Diversity, and Shannon Index were conducted on rarefied samples using phyloseq (McMurdie and Holmes 2013) and picante (Kembel et al. 2010) libraries. Beta diversity was determined using both weighted and unweighted UniFrac distance matrices (Lozupone and Knight 2005), generated in phyloseq. The *Bacteroides Prevotella* ratio was calculated by dividing the abundance of the genera *Bacteroides* by *Prevotella*. Participants were classified into *Bacteroides* enterotype (B-type) if the ratio was greater than 1, otherwise *Prevotella* enterotype (P-type). For differential abundance analysis, samples were processed to remove exceptionally rare taxa. First, the non-rarefied reads were filtered to remove samples with < 10,000 reads. Next, ASVs with fewer than 50 reads in total across all samples and/or were present in less than 2% of samples were excluded. This retained 2061 ASVs across 1694 samples. The retained ASVs were binned at genus level, and subsequently used in the analysis of compositions of microbiomes with bias correction (ANCOMBC; (H. Lin and Peddada 2020) to determine specific taxa differentially abundant across sites or obese phenotype. ANCOM-BC is a statistical approach that accounts for sampling fraction, normalizes the read counts by a process identical to log-ratio transformations while controlling for false discovery rates and increasing power. Site, age, sex, BMI were added as covariates in the ANCOM-BC formula to reduce the effect of confounders.

*Random forest classifier:* Random Forest supervised learning models implemented in Qiime2 were used to estimate the predictive power of microbial community profiles for site and obese phenotype. The classifications were done with 500 trees based on 10-fold cross-validation using the QIIME "sample-classifier classify-samples" plugin (Bokulich et al. 2018). A randomly drawn 80% of samples were used for model training, whereas the remaining 20% were used for validation. Further, the 30 most important ASVs for differentiating between site or obese phenotype were predicted and annotated.



*Predicted metabolic gene pathway analysis:* The functional potential of microbial communities was inferred using the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) v2.5.1 with the ASV table processed to remove exceptionally rare taxa and the representative sequences as input files (Douglas et al. 2020). The metabolic pathway from the PICRUSt2 pipeline was annotated using the MetaCyc database (Caspi et al. 2016). The predicted MetaCyc abundances (unstratified pathway abundances) were analyzed with ANCOM-BC to determine differentially abundant pathway associations across sites and obese status. Site, age, sex, BMI were added as covariates in the ANCOM-BC formula to reduce the effect of confounders.

*Statistical Analysis:* All statistical analyses and graphs were done with R software. Kruskal-Wallis test and Permutational Analysis of Variance (PERMANOVA) test with 999 permutations using the Adonis function in the vegan package (Oksanen et al. 2013) were performed to compare alpha and beta diversity measures respectively with multiple groups comparison correction. PERMANOVA models were adjusted for BMI, age, sex for country whereas age, sex and country were accounted for in obese groups. Variables that showed significant differences in the PERMANOVA analyses, PERMDISP test was performed to assess differences in dispersion or centroids. For differential abundance analysis, the false-discovery rate (FDR) method incorporated in the ANCOM-BC library was used to correct p-values for multiple testing. A cut-off of  $P_{adj} < 0.05$  was used to assess significance. Spearman correlations were performed between concentrations of short chain fatty acids, Shannon diversity or concentrations of short chain fatty acids and differentially abundant taxa that were identified either among study sites or in obese and non-obese individuals. The resulting p-values were adjusted for multiple testing using the false-discovery rate (FDR). P value  $< 0.05$  was considered statistically significant. A mixed model was built using lme4 package to assess whether total SCFAs could be predicted by Shannon diversity, obesity, and country, setting obesity and Shannon diversity as fixed effects and random intercept by country.

*Data availability.* All 16S rRNA gene sequence data are publicly available via the QIITA platform (<https://qiita.ucsd.edu>) under the study identifier (ID=13512) and will soon be deposited on the European Bioinformatics Institute (EBI) site. The SILVA 16 S rRNA database used for alignment is available at <https://data.qiime2.org/2022.2/common/silva-138-99-515-806-nb-classifier.qza>. The data and analyses generated in this study are available within the paper, Supplementary Information and Source data files provided with this paper.

## **Declarations**

### ***Acknowledgements***

We thank the METS participants who continue their ongoing participation in the METS studies, as well as the site-specific clinic staff in Ghana, South Africa, Jamaica, Seychelles and the US. The UCSD Microbiome Core performed sample extractions and library preparation utilizing protocols and primers published on the Earth Microbiome Project website (<https://earthmicrobiome.org/>). This publication

includes data generated at the UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929).

### ***Contributions***

LRD and BTL conceived the study. LRD, CC-K, PB, KB-A, JP-R, TEF, EVL, DR and AL collected human samples and metadata. GE-M, CC-K, DR and AL curated metadata. SD performed sequencing of samples. GE-M, CC-K and MGM conducted formal analysis and visualization. JAG and LRD supervised and provided feedback on formal analysis and visualization. GE-M, CC-K, MGM, LRD and JAG wrote the original manuscript. LRD secured the funding. All authors edited and approved the final manuscript.

### ***Funding***

This work is supported by the National Institutes of Health grant R01-DK111848

## **References**

1. Abdelaal, Mahmoud, Carel W. le Roux, and Neil G. Docherty. 2017. "Morbidity and Mortality Associated with Obesity." *Annals of Translational Medicine* 5 (7): 161.
2. Agyemang, Charles, Sandra Boatemaa, Grace Agyemang Frempong, and Ama de-Graft Aikins. 2016. "Obesity in Sub-Saharan Africa." In *Metabolic Syndrome: A Comprehensive Textbook*, edited by Rexford S. Ahima, 41–53. Cham: Springer International Publishing.
3. Ajala, O., F. Mold, C. Boughton, D. Cooke, and M. Whyte. 2017. "Childhood Predictors of Cardiovascular Disease in Adulthood. A Systematic Review and Meta-Analysis." *Obesity Reviews: An Official Journal of the International Association for the Study of Obesity* 18 (9): 1061–70.
4. Amir, Amnon, Daniel McDonald, Jose A. Navas-Molina, Evguenia Kopylova, James T. Morton, Zhenjiang Zech Xu, Eric P. Kightley, et al. 2017. "Deblur Rapidly Resolves Single-Nucleotide Community Sequence Patterns." *MSystems* 2 (2). <https://doi.org/10.1128/mSystems.00191-16>.
5. Arumugam, Manimozhiyan, Jeroen Raes, Eric Pelletier, Denis Le Paslier, Takuji Yamada, Daniel R. Mende, Gabriel R. Fernandes, et al. 2011. "Enterotypes of the Human Gut Microbiome." *Nature* 473 (7346): 174–80.
6. Asnicar, Francesco, Sarah E. Berry, Ana M. Valdes, Long H. Nguyen, Gianmarco Piccinno, David A. Drew, Emily Leeming, et al. 2021. "Microbiome Connections with Host Metabolism and Habitual Diet from 1,098 Deeply Phenotyped Individuals." *Nature Medicine* 27 (2): 321–32.
7. Bäckhed, Fredrik, Jill K. Manchester, Clay F. Semenkovich, and Jeffrey I. Gordon. 2007. "Mechanisms Underlying the Resistance to Diet-Induced Obesity in Germ-Free Mice." *Proceedings of the National Academy of Sciences of the United States of America* 104 (3): 979–84.
8. Barengolts, Elena, Stefan J. Green, George E. Chlipala, Brian T. Layden, Yuval Eisenberg, Medha Priyadarshini, and Lara R. Dugas. 2019. "Predictors of Obesity among Gut Microbiota Biomarkers in

- African American Men with and without Diabetes." *Microorganisms* 7 (9).  
<https://doi.org/10.3390/microorganisms7090320>.
9. Barone, Monica, Silvia Garelli, Simone Rampelli, Alessandro Agostini, Silke Matysik, Federica D'Amico, Sabrina Krautbauer, et al. 2022. "Multi-Omics Gut Microbiome Signatures in Obese Women: Role of Diet and Uncontrolled Eating Behavior." *BMC Medicine* 20 (1): 500.
  10. Beaumont, Michelle, Julia K. Goodrich, Matthew A. Jackson, Idil Yet, Emily R. Davenport, Sara Vieira-Silva, Justine Debelius, et al. 2016. "Heritable Components of the Human Fecal Microbiome Are Associated with Visceral Fat." *Genome Biology* 17 (1): 189.
  11. Bokulich, Nicholas A., Benjamin D. Kaehler, Jai Ram Rideout, Matthew Dillon, Evan Bolyen, Rob Knight, Gavin A. Huttley, and J. Gregory Caporaso. 2018. "Optimizing Taxonomic Classification of Marker-Gene Amplicon Sequences with QIIME 2's Q2-Feature-Classifer Plugin." *Microbiome* 6 (1): 90.
  12. Bolyen, Evan, Jai Ram Rideout, Matthew R. Dillon, Nicholas A. Bokulich, Christian C. Abnet, Gabriel A. Al-Ghalith, Harriet Alexander, et al. 2019. "Reproducible, Interactive, Scalable and Extensible Microbiome Data Science Using QIIME 2." *Nature Biotechnology* 37 (8): 852–57.
  13. Bonomo, Raiza R., Tyler M. Cook, Chaitanya K. Gavini, Chelsea R. White, Jacob R. Jones, Elisa Bovo, Aleksey V. Zima, et al. 2020. "Fecal Transplantation and Butyrate Improve Neuropathic Pain, Modify Immune Cell Profile, and Gene Expression in the PNS of Obese Mice." *Proceedings of the National Academy of Sciences of the United States of America* 117 (42): 26482–93.
  14. Boulangé, Claire L., Ana Luisa Neves, Julien Chilloux, Jeremy K. Nicholson, and Marc-Emmanuel Dumas. 2016. "Impact of the Gut Microbiota on Inflammation, Obesity, and Metabolic Disease." *Genome Medicine* 8 (1): 42.
  15. Canfora, Emanuel E., Johan W. Jocken, and Ellen E. Blaak. 2015. "Short-Chain Fatty Acids in Control of Body Weight and Insulin Sensitivity." *Nature Reviews. Endocrinology* 11 (10): 577–91.
  16. Cani, Patrice D., Jacques Amar, Miguel Angel Iglesias, Marjorie Poggi, Claude Knauf, Delphine Bastelica, Audrey M. Neyrinck, et al. 2007. "Metabolic Endotoxemia Initiates Obesity and Insulin Resistance." *Diabetes* 56 (7): 1761–72.
  17. Cani, Patrice D., Rodrigo Bibiloni, Claude Knauf, Aurélie Waget, Audrey M. Neyrinck, Nathalie M. Delzenne, and Rémy Burcelin. 2008. "Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice." *Diabetes* 57 (6): 1470–81.
  18. Cani, Patrice D., and Nathalie M. Delzenne. 2009. "Interplay between Obesity and Associated Metabolic Disorders: New Insights into the Gut Microbiota." *Current Opinion in Pharmacology* 9 (6): 737–43.
  19. Caspi, Ron, Richard Billington, Luciana Ferrer, Hartmut Foerster, Carol A. Fulcher, Ingrid M. Keseler, Anamika Kothari, et al. 2016. "The MetaCyc Database of Metabolic Pathways and Enzymes and the BioCyc Collection of Pathway/Genome Databases." *Nucleic Acids Research* 44 (D1): D471-80.
  20. Chambers, Edward S., Alexander Viardot, Arianna Psichas, Douglas J. Morrison, Kevin G. Murphy, Sagen E. K. Zac-Varghese, Kenneth MacDougall, et al. 2015. "Effects of Targeted Delivery of

- Propionate to the Human Colon on Appetite Regulation, Body Weight Maintenance and Adiposity in Overweight Adults." *Gut* 64 (11): 1744–54.
21. Chen, Nathan H., Karrera Y. Djoko, Frédéric J. Veyrier, and Alastair G. McEwan. 2016. "Formaldehyde Stress Responses in Bacterial Pathogens." *Frontiers in Microbiology* 7 (March): 257.
  22. Chen, Tingting, Wenmin Long, Chenhong Zhang, Shuang Liu, Liping Zhao, and Bruce R. Hamaker. 2017. "Fiber-Utilizing Capacity Varies in Prevotella- versus Bacteroides-Dominated Gut Microbiota." *Scientific Reports* 7 (1): 2594.
  23. Clemente, Jose C., Erica C. Pehrsson, Martin J. Blaser, Kuldip Sandhu, Zhan Gao, Bin Wang, Magda Magris, et al. 2015. "The Microbiome of Uncontacted Amerindians." *Science Advances* 1 (3). <https://doi.org/10.1126/sciadv.1500183>.
  24. Companys, Judit, Maria José Gosalbes, Laura Pla-Pagà, Lorena Calderón-Pérez, Elisabet Llauradó, Anna Pedret, Rosa Maria Valls, et al. 2021. "Gut Microbiota Profile and Its Association with Clinical Variables and Dietary Intake in Overweight/Obese and Lean Subjects: A Cross-Sectional Study." *Nutrients* 13 (6). <https://doi.org/10.3390/nu13062032>.
  25. Costello, Elizabeth K., Keaton Stagaman, Les Dethlefsen, Brendan J. M. Bohannan, and David A. Relman. 2012. "The Application of Ecological Theory toward an Understanding of the Human Microbiome." *Science* 336 (6086): 1255–62.
  26. Cuesta-Zuluaga, Jacobo de la, Vanessa Corrales-Agudelo, Eliana P. Velásquez-Mejía, Jenny A. Carmona, José M. Abad, and Juan S. Escobar. 2018. "Gut Microbiota Is Associated with Obesity and Cardiometabolic Disease in a Population in the Midst of Westernization." *Scientific Reports* 8 (1): 11356.
  27. Cuesta-Zuluaga, Jacobo de la, Noel T. Mueller, Rafael Álvarez-Quintero, Eliana P. Velásquez-Mejía, Jelver A. Sierra, Vanessa Corrales-Agudelo, Jenny A. Carmona, José M. Abad, and Juan S. Escobar. 2018. "Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors." *Nutrients* 11 (1). <https://doi.org/10.3390/nu11010051>.
  28. Dahl, Wendy J., and Maria L. Stewart. 2015. "Position of the Academy of Nutrition and Dietetics: Health Implications of Dietary Fiber." *Journal of the Academy of Nutrition and Dietetics* 115 (11): 1861–70.
  29. Dalile, Boushra, Lukas Van Oudenhove, Bram Vervliet, and Kristin Verbeke. 2019. "The Role of Short-Chain Fatty Acids in Microbiota-Gut-Brain Communication." *Nature Reviews. Gastroenterology & Hepatology* 16 (8): 461–78.
  30. De Filippis, Francesca, Nicoletta Pellegrini, Lucia Vannini, Ian B. Jeffery, Antonietta La Stora, Luca Laghi, Diana I. Serrazanetti, et al. 2016. "High-Level Adherence to a Mediterranean Diet Beneficially Impacts the Gut Microbiota and Associated Metabolome." *Gut* 65 (11): 1812–21.
  31. De Filippo, Carlotta, Duccio Cavalieri, Monica Di Paola, Matteo Ramazzotti, Jean Baptiste Poullet, Sebastien Massart, Silvia Collini, Giuseppe Pieraccini, and Paolo Lionetti. 2010. "Impact of Diet in Shaping Gut Microbiota Revealed by a Comparative Study in Children from Europe and Rural Africa."

- Proceedings of the National Academy of Sciences of the United States of America* 107 (33): 14691–96.
32. De Filippo, Carlotta, Monica Di Paola, Matteo Ramazzotti, Davide Albanese, Giuseppe Pieraccini, Elena Banci, Franco Miglietta, Duccio Cavalieri, and Paolo Lionetti. 2017. "Diet, Environments, and Gut Microbiota. A Preliminary Investigation in Children Living in Rural and Urban Burkina Faso and Italy." *Frontiers in Microbiology* 8 (October): 1979.
  33. DiBaise, John K., Husen Zhang, Michael D. Crowell, Rosa Krajmalnik-Brown, G. Anton Decker, and Bruce E. Rittmann. 2008. "Gut Microbiota and Its Possible Relationship with Obesity." *Mayo Clinic Proceedings. Mayo Clinic* 83 (4): 460–69.
  34. Douglas, Gavin M., Vincent J. Maffei, Jesse R. Zaneveld, Svetlana N. Yurgel, James R. Brown, Christopher M. Taylor, Curtis Huttenhower, and Morgan G. I. Langille. 2020. "PICRUSt2 for Prediction of Metagenome Functions." *Nature Biotechnology* 38 (6): 685–88.
  35. Dugas, Lara R., Beatriz Peñalver Bernabé, Medha Priyadarshini, Na Fei, Seo Jin Park, Laquita Brown, Jacob Plange-Rhule, et al. 2018. "Decreased Microbial Co-Occurrence Network Stability and SCFA Receptor Level Correlates with Obesity in African-Origin Women." *Scientific Reports* 8 (1): 17135.
  36. Dugas, Lara R., Louise Lie, Jacob Plange-Rhule, Kweku Bedu-Addo, Pascal Bovet, Estelle V. Lambert, Terrence E. Forrester, Amy Luke, Jack A. Gilbert, and Brian T. Layden. 2018. "Gut Microbiota, Short Chain Fatty Acids, and Obesity across the Epidemiologic Transition: The METS-Microbiome Study Protocol." *BMC Public Health* 18 (1): 978.
  37. Ecklu-Mensah, Gertrude, Jack Gilbert, and Suzanne Devkota. 2022. "Dietary Selection Pressures and Their Impact on the Gut Microbiome." *Cellular and Molecular Gastroenterology and Hepatology* 13 (1): 7–18.
  38. Esposito, Katherine, Christina-Maria Kastorini, Demosthenes B. Panagiotakos, and Dario Giugliano. 2011. "Mediterranean Diet and Weight Loss: Meta-Analysis of Randomized Controlled Trials." *Metabolic Syndrome and Related Disorders* 9 (1): 1–12.
  39. Falony, Gwen, Marie Joossens, Sara Vieira-Silva, Jun Wang, Youssef Darzi, Karoline Faust, Alexander Kurilshikov, et al. 2016. "Population-Level Analysis of Gut Microbiome Variation." *Science* 352 (6285): 560–64.
  40. Fei, Na, Beatriz Peñalver Bernabé, Louise Lie, Danny Baghdan, Kweku Bedu-Addo, Jacob Plange-Rhule, Terrence E. Forrester, et al. 2019. "The Human Microbiota Is Associated with Cardiometabolic Risk across the Epidemiologic Transition." *PloS One* 14 (7): e0215262.
  41. Fei, Na, Candice Choo-Kang, Sirimon Reutrakul, Stephanie J. Crowley, Dale Rae, Kweku Bedu-Addo, Jacob Plange-Rhule, et al. 2021. "Gut Microbiota Alterations in Response to Sleep Length among African-Origin Adults." *PloS One* 16 (9): e0255323.
  42. Fei, Na, and Liping Zhao. 2013. "An Opportunistic Pathogen Isolated from the Gut of an Obese Human Causes Obesity in Germfree Mice." *The ISME Journal* 7 (4): 880–84.
  43. Fernandes, J., W. Su, S. Rahat-Rozenbloom, T. M. S. Wolever, and E. M. Comelli. 2014. "Adiposity, Gut Microbiota and Faecal Short Chain Fatty Acids Are Linked in Adult Humans." *Nutrition & Diabetes* 4

(6): e121.

44. Finucane, Mariel M., Thomas J. Sharpton, Timothy J. Laurent, and Katherine S. Pollard. 2014. "A Taxonomic Signature of Obesity in the Microbiome? Getting to the Guts of the Matter." *PloS One* 9 (1): e84689.
45. Gao, Zhanguo, Jun Yin, Jin Zhang, Robert E. Ward, Roy J. Martin, Michael Lefevre, William T. Cefalu, and Jianping Ye. 2009. "Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice." *Diabetes* 58 (7): 1509–17.
46. Geng, Jiafeng, Qingqiang Ni, Wei Sun, Liangge Li, and Xiuqing Feng. 2022. "The Links between Gut Microbiota and Obesity and Obesity Related Diseases." *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie* 147 (March): 112678.
47. Gomez, Andres, Klara J. Petrzekova, Michael B. Burns, Carl J. Yeoman, Katherine R. Amato, Klara Vlckova, David Modry, et al. 2016. "Gut Microbiome of Coexisting BaAka Pygmies and Bantu Reflects Gradients of Traditional Subsistence Patterns." *Cell Reports* 14 (9): 2142–53.
48. Gonzalez, Antonio, Jose A. Navas-Molina, Tomasz Kosciolk, Daniel McDonald, Yoshiki Vázquez-Baeza, Gail Ackermann, Jeff DeReus, et al. 2018. "Qiita: Rapid, Web-Enabled Microbiome Meta-Analysis." *Nature Methods* 15 (10): 796–98.
49. Gophna, Uri, Tom Konikoff, and Henrik Bjørn Nielsen. 2017. "Oscillospira and Related Bacteria - From Metagenomic Species to Metabolic Features." *Environmental Microbiology* 19 (3): 835–41.
50. Gouda, Hebe N., Fiona Charlson, Katherine Sorsdahl, Sanam Ahmadzada, Alize J. Ferrari, Holly Erskine, Janni Leung, et al. 2019. "Burden of Non-Communicable Diseases in Sub-Saharan Africa, 1990-2017: Results from the Global Burden of Disease Study 2017." *The Lancet. Global Health* 7 (10): e1375–87.
51. Greenblum, Sharon, Peter J. Turnbaugh, and Elhanan Borenstein. 2012. "Metagenomic Systems Biology of the Human Gut Microbiome Reveals Topological Shifts Associated with Obesity and Inflammatory Bowel Disease." *Proceedings of the National Academy of Sciences of the United States of America* 109 (2): 594–99.
52. Gupta, Vinod K., Sandip Paul, and Chitra Dutta. 2017. "Geography, Ethnicity or Subsistence-Specific Variations in Human Microbiome Composition and Diversity." *Frontiers in Microbiology* 8 (June): 1162.
53. Hales, Craig M., Margaret D. Carroll, Cheryl D. Fryar, and Cynthia L. Ogden. 2020. "Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018." *NCHS Data Brief*, no. 360 (February): 1–8.
54. He, Yan, Wei Wu, Hui-Min Zheng, Pan Li, Daniel McDonald, Hua-Fang Sheng, Mu-Xuan Chen, et al. 2018. "Regional Variation Limits Applications of Healthy Gut Microbiome Reference Ranges and Disease Models." *Nature Medicine* 24 (10): 1532–35.
55. Hee, Bart van der, and Jerry M. Wells. 2021. "Microbial Regulation of Host Physiology by Short-Chain Fatty Acids." *Trends in Microbiology* 29 (8): 700–712.

56. Henagan, Tara M., Barbara Stefanska, Zhide Fang, Alexandra M. Navard, Jianping Ye, Natalie R. Lenard, and Prasad P. Devarshi. 2015. "Sodium Butyrate Epigenetically Modulates High-Fat Diet-Induced Skeletal Muscle Mitochondrial Adaptation, Obesity and Insulin Resistance through Nucleosome Positioning." *British Journal of Pharmacology* 172 (11): 2782–98.
57. Hu, Xiaojie, Jinlong Gao, Qianyuan Zhang, Yuanqing Fu, Kelei Li, Shankuan Zhu, and Duo Li. 2013. "Soy Fiber Improves Weight Loss and Lipid Profile in Overweight and Obese Adults: A Randomized Controlled Trial." *Molecular Nutrition & Food Research* 57 (12): 2147–54.
58. Jumpertz, Reiner, Duc Son Le, Peter J. Turnbaugh, Cathy Trinidad, Clifton Bogardus, Jeffrey I. Gordon, and Jonathan Krakoff. 2011. "Energy-Balance Studies Reveal Associations between Gut Microbes, Caloric Load, and Nutrient Absorption in Humans." *The American Journal of Clinical Nutrition* 94 (1): 58–65.
59. Kao, Christina C., Julia L. Cope, Jean W. Hsu, Pratibha Dwarkanath, Jeffrey M. Karnes, Ruth A. Luna, Emily B. Hollister, Minerva M. Thame, Anura V. Kurpad, and Farook Jahoor. 2015. "The Microbiome, Intestinal Function, and Arginine Metabolism of Healthy Indian Women Are Different from Those of American and Jamaican Women." *The Journal of Nutrition* 146 (4): 706–13.
60. Karlsson, Fredrik H., Frida Fåk, Intawat Nookaew, Valentina Tremaroli, Björn Fagerberg, Dina Petranovic, Fredrik Bäckhed, and Jens Nielsen. 2012. "Symptomatic Atherosclerosis Is Associated with an Altered Gut Metagenome." *Nature Communications* 3: 1245.
61. Kembel, Steven W., Peter D. Cowan, Matthew R. Helmus, William K. Cornwell, Helene Morlon, David D. Ackerly, Simon P. Blomberg, and Campbell O. Webb. 2010. "Picante: R Tools for Integrating Phylogenies and Ecology." *Bioinformatics* 26 (11): 1463–64.
62. Kim, Mi-Hyun, Kyung Eun Yun, Jimin Kim, Eunkyo Park, Yoosoo Chang, Seungho Ryu, Hyung-Lae Kim, and Han-Na Kim. 2020. "Gut Microbiota and Metabolic Health among Overweight and Obese Individuals." *Scientific Reports* 10 (1): 19417.
63. Kim, Sun-Young, Eunkyo Park, Weon-Jeong Lim, Soo In Kim, Sang Won Jeon, Yoosoo Chang, Seungho Ryu, Hyung-Lae Kim, and Han-Na Kim. 2022. "Association Between Gut Microbiota and Depressive Symptoms: A Cross-Sectional Population-Based Study in South Korea." *Psychosomatic Medicine* 84 (7): 757–65.
64. Koh, Ara, Filipe De Vadder, Petia Kovatcheva-Datchary, and Fredrik Bäckhed. 2016. "From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites." *Cell* 165 (6): 1332–45.
65. Kolodziejczyk, Aleksandra A., Danping Zheng, and Eran Elinav. 2019. "Diet-Microbiota Interactions and Personalized Nutrition." *Nature Reviews. Microbiology* 17 (12): 742–53.
66. Konikoff, Tom, and Uri Gophna. 2016. "Oscillospira: A Central, Enigmatic Component of the Human Gut Microbiota." *Trends in Microbiology* 24 (7): 523–24.
67. Le Chatelier, Emmanuelle, Trine Nielsen, Junjie Qin, Edi Prifti, Falk Hildebrand, Gwen Falony, Mathieu Almeida, et al. 2013. "Richness of Human Gut Microbiome Correlates with Metabolic Markers." *Nature* 500 (7464): 541–46.

68. Leone, Vanessa, Sean M. Gibbons, Kristina Martinez, Alan L. Hutchison, Edmond Y. Huang, Candace M. Cham, Joseph F. Pierre, et al. 2015. "Effects of Diurnal Variation of Gut Microbes and High-Fat Feeding on Host Circadian Clock Function and Metabolism." *Cell Host & Microbe* 17 (5): 681–89.
69. Lewandowski, Cutler T., Md Wasim Khan, Manel BenAissa, Oleksii Dubrovskiy, Martha Ackerman-Berrier, Mary Jo LaDu, Brian T. Layden, and Gregory R. J. Thatcher. 2021. "Metabolomic Analysis of a Selective ABCA1 Inducer in Obesogenic Challenge Provides a Rationale for Therapeutic Development." *EBioMedicine* 66 (April): 103287.
70. Ley, Ruth E. 2010. "Obesity and the Human Microbiome." *Current Opinion in Gastroenterology* 26 (1): 5–11.
71. Ley, Ruth E., Fredrik Bäckhed, Peter Turnbaugh, Catherine A. Lozupone, Robin D. Knight, and Jeffrey I. Gordon. 2005. "Obesity Alters Gut Microbial Ecology." *Proceedings of the National Academy of Sciences of the United States of America* 102 (31): 11070–75.
72. Ley, Ruth E., Peter J. Turnbaugh, Samuel Klein, and Jeffrey I. Gordon. 2006. "Microbial Ecology: Human Gut Microbes Associated with Obesity." *Nature* 444 (7122): 1022–23.
73. Lin, Hua V., Andrea Frassetto, Edward J. Kowalik Jr, Andrea R. Nawrocki, Mofei M. Lu, Jennifer R. Kosinski, James A. Hubert, et al. 2012. "Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms." *PloS One* 7 (4): e35240.
74. Lin, Huang, and Shyamal Das Peddada. 2020. "Analysis of Compositions of Microbiomes with Bias Correction." *Nature Communications* 11 (1): 3514.
75. Lippert, K., L. Kedenko, L. Antonielli, I. Kedenko, C. Gemeier, M. Leitner, A. Kautzky-Willer, B. Paulweber, and E. Hackl. 2017. "Gut Microbiota Dysbiosis Associated with Glucose Metabolism Disorders and the Metabolic Syndrome in Older Adults." *Beneficial Microbes* 8 (4): 545–56.
76. Liu, Xiaoxia, Ke Zhao, Nana Jing, Qingjun Kong, and Xingbin Yang. 2021. "Epigallocatechin Gallate (EGCG) Promotes the Immune Function of Ileum in High Fat Diet Fed Mice by Regulating Gut Microbiome Profiling and Immunoglobulin Production." *Frontiers in Nutrition* 8 (September): 720439.
77. Lozupone, Catherine, and Rob Knight. 2005. "UniFrac: A New Phylogenetic Method for Comparing Microbial Communities." *Applied and Environmental Microbiology* 71 (12): 8228–35.
78. Lu, Yuanyuan, Chaonan Fan, Ping Li, Yanfei Lu, Xuelian Chang, and Kemin Qi. 2016. "Short Chain Fatty Acids Prevent High-Fat-Diet-Induced Obesity in Mice by Regulating G Protein-Coupled Receptors and Gut Microbiota." *Scientific Reports* 6 (November): 37589.
79. Luke, Amy, Pascal Bovet, Terrence E. Forrester, Estelle V. Lambert, Jacob Plange-Rhule, Dale A. Schoeller, Lara R. Dugas, et al. 2011. "Protocol for the Modeling the Epidemiologic Transition Study: A Longitudinal Observational Study of Energy Balance and Change in Body Weight, Diabetes and Cardiovascular Disease Risk." *BMC Public Health* 11 (December): 927.
80. Mancabelli, Leonardo, Christian Milani, Gabriele Andrea Lugli, Francesca Turrone, Chiara Ferrario, Douwe van Sinderen, and Marco Ventura. 2017. "Meta-Analysis of the Human Gut Microbiome from Urbanized and Pre-Agricultural Populations." *Environmental Microbiology* 19 (4): 1379–90.



81. Marchesi, Julian R., David H. Adams, Francesca Fava, Gerben D. A. Hermes, Gideon M. Hirschfield, Georgina Hold, Mohammed Nabil Quraishi, et al. 2016. "The Gut Microbiota and Host Health: A New Clinical Frontier." *Gut* 65 (2): 330–39.
82. McLaren, Michael R. 2020. *Silva SSU Taxonomic Training Data Formatted for DADA2 (Silva Version 138)*. <https://doi.org/10.5281/zenodo.3731176>.
83. McMurdie, Paul J., and Susan Holmes. 2013. "Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data." *PloS One* 8 (4): e61217.
84. Meehan, Conor J., and Robert G. Beiko. 2014. "A Phylogenomic View of Ecological Specialization in the Lachnospiraceae, a Family of Digestive Tract-Associated Bacteria." *Genome Biology and Evolution* 6 (3): 703–13.
85. Mehta, Supal, Lara Ruth Dugas, Candice Choo-Kang, Pascal Bovet, Terrence Forrester, Kweku Bedu-Addo, Estelle Vicki Lambert, et al. 2021. "Consumption of Monounsaturated Fatty Acids Is Associated with Improved Cardiometabolic Outcomes in Four African-Origin Populations Spanning the Epidemiologic Transition." *Nutrients* 13 (7). <https://doi.org/10.3390/nu13072442>.
86. Mirarab, S., N. Nguyen, and T. Warnow. 2012. "SEPP: SATé-Enabled Phylogenetic Placement." *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*, 247–58.
87. Moreau, N. M., S. M. Goupry, J. P. Antignac, F. J. Monteau, B. J. Le Bizec, M. M. Champ, L. J. Martin, and H. J. Dumon. 2003. "Simultaneous Measurement of Plasma Concentrations and <sup>13</sup>C-Enrichment of Short-Chain Fatty Acids, Lactic Acid and Ketone Bodies by Gas Chromatography Coupled to Mass Spectrometry." *Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences* 784 (2): 395–403.
88. Morotomi, Masami, Fumiko Nagai, and Yohei Watanabe. 2012. "Description of *Christensenella* *Minuta* Gen. Nov., Sp. Nov., Isolated from Human Faeces, Which Forms a Distinct Branch in the Order Clostridiales, and Proposal of Christensenellaceae Fam. Nov." *International Journal of Systematic and Evolutionary Microbiology* 62 (Pt 1): 144–49.
89. "National Diabetes Statistics Report." 2022. June 29, 2022. <https://www.cdc.gov/diabetes/data/statistics-report/index.html>.
90. Navarro, Guadalupe, Anukriti Sharma, Lara R. Dugas, Terrence Forrester, Jack A. Gilbert, and Brian T. Layden. 2018. "Gut Microbial Features Can Predict Host Phenotype Response to Protein Deficiency." *Physiological Reports* 6 (23): e13932.
91. Newton, Gerald L., Nancy Buchmeier, and Robert C. Fahey. 2008. "Biosynthesis and Functions of Mycothiol, the Unique Protective Thiol of Actinobacteria." *Microbiology and Molecular Biology Reviews: MMBR* 72 (3): 471–94.
92. Nooromid, Michael, Edmund B. Chen, Liqun Xiong, Katherine Shapiro, Qun Jiang, Falen Demsas, Maeve Eskandari, et al. 2020. "Microbe-Derived Butyrate and Its Receptor, Free Fatty Acid Receptor 3, But Not Free Fatty Acid Receptor 2, Mitigate Neointimal Hyperplasia Susceptibility After Arterial Injury." *Journal of the American Heart Association* 9 (13): e016235.

93. Nordmo, Morten, Yngvild Sørensen, and Magnus Nordmo. 2020. "The Challenge of Keeping It off, a Descriptive Systematic Review of High-Quality, Follow-up Studies of Obesity Treatments." *Obesity Reviews: An Official Journal of the International Association for the Study of Obesity* 21 (1): e12949.
94. "Obesity and Overweight." n.d. Accessed February 25, 2023. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.
95. Oksanen, J., F. G. Blanchet, R. Kindt, P. Legendre, and H. Wagner. 2013. "Vegan: Community Ecology Package. R Package Version. 2.0-10," January. <http://dx.doi.org/>.
96. Pasolli, Edoardo, Francesco Asnicar, Serena Manara, Moreno Zolfo, Nicolai Karcher, Federica Armanini, Francesco Beghini, et al. 2019. "Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle." *Cell* 176 (3): 649-662.e20.
97. Peters, Brandilyn A., Jean A. Shapiro, Timothy R. Church, George Miller, Chau Trinh-Shevrin, Elizabeth Yuen, Charles Friedlander, Richard B. Hayes, and Jiyoung Ahn. 2018. "A Taxonomic Signature of Obesity in a Large Study of American Adults." *Scientific Reports* 8 (1): 9749.
98. Qin, Junjie, Yingrui Li, Zhiming Cai, Shenghui Li, Jianfeng Zhu, Fan Zhang, Suisha Liang, et al. 2012. "A Metagenome-Wide Association Study of Gut Microbiota in Type 2 Diabetes." *Nature* 490 (7418): 55–60.
99. Rahat-Rozenbloom, S., J. Fernandes, G. B. Gloor, and T. M. S. Wolever. 2014. "Evidence for Greater Production of Colonic Short-Chain Fatty Acids in Overweight than Lean Humans." *International Journal of Obesity* 38 (12): 1525–31.
100. Rampelli, Simone, Stephanie L. Schnorr, Clarissa Consolandi, Silvia Turrone, Marco Severgnini, Clelia Peano, Patrizia Brigidi, Alyssa N. Crittenden, Amanda G. Henry, and Marco Candela. 2015. "Metagenome Sequencing of the Hadza Hunter-Gatherer Gut Microbiota." *Current Biology: CB* 25 (13): 1682–93.
101. Reiman, Derek, Brian T. Layden, and Yang Dai. 2021. "MiMeNet: Exploring Microbiome-Metabolome Relationships Using Neural Networks." *PLoS Computational Biology* 17 (5): e1009021.
102. Reingruber, Hernán, and Lucas Blas Pontel. 2018. "Formaldehyde Metabolism and Its Impact on Human Health." *Current Opinion in Toxicology* 9 (June): 28–34.
103. Richardson, A. J., A. G. Calder, C. S. Stewart, and A. Smith. 1989. "Simultaneous Determination of Volatile and Non-volatile Acidic Fermentation Products of Anaerobes by Capillary Gas Chromatography." *Letters in Applied Microbiology* 9 (1): 5–8.
104. Ridaura, Vanessa K., Jeremiah J. Faith, Federico E. Rey, Jiye Cheng, Alexis E. Duncan, Andrew L. Kau, Nicholas W. Griffin, et al. 2013. "Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice." *Science* 341 (6150): 1241214.
105. Riva, Alessandra, Francesca Borgo, Carlotta Lassandro, Elvira Verduci, Giulia Morace, Elisa Borghi, and David Berry. 2017. "Pediatric Obesity Is Associated with an Altered Gut Microbiota and Discordant Shifts in Firmicutes Populations." *Environmental Microbiology* 19 (1): 95–105.

106. Roth, Gregory A., George A. Mensah, Catherine O. Johnson, Giovanni Addolorato, Enrico Ammirati, Larry M. Baddour, Noël C. Barengo, et al. 2020. "Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study." *Journal of the American College of Cardiology* 76 (25): 2982–3021.
107. Sanna, Serena, Natalie R. van Zuydam, Anubha Mahajan, Alexander Kurilshikov, Arnau Vich Vila, Urmo Vösa, Zlatan Mujagic, et al. 2019. "Causal Relationships among the Gut Microbiome, Short-Chain Fatty Acids and Metabolic Diseases." *Nature Genetics* 51 (4): 600–605.
108. Schnorr, Stephanie L., Marco Candela, Simone Rampelli, Manuela Centanni, Clarissa Consolandi, Giulia Basaglia, Silvia Turrone, et al. 2014. "Gut Microbiome of the Hadza Hunter-Gatherers." *Nature Communications* 5 (April): 3654.
109. Schwartz, Andreas, David Taras, Klaus Schäfer, Silvia Beijer, Nicolaas A. Bos, Christiane Donus, and Philip D. Hardt. 2010. "Microbiota and SCFA in Lean and Overweight Healthy Subjects." *Obesity* 18 (1): 190–95.
110. Sonnenburg, Erica D., and Justin L. Sonnenburg. 2019. "The Ancestral and Industrialized Gut Microbiota and Implications for Human Health." *Nature Reviews. Microbiology* 17 (6): 383–90.
111. Sonnenburg, Justin L., and Fredrik Bäckhed. 2016. "Diet-Microbiota Interactions as Moderators of Human Metabolism." *Nature* 535 (7610): 56–64.
112. Stanislowski, Maggie A., Dana Dabelea, Brandie D. Wagner, Marci K. Sontag, Catherine A. Lozupone, and Merete Eggesbø. 2017. "Pre-Pregnancy Weight, Gestational Weight Gain, and the Gut Microbiota of Mothers and Their Infants." *Microbiome* 5 (1): 113.
113. Teixeira, Tatiana F. S., Łukasz Grześkowiak, Sylvia C. C. Franceschini, Josefina Bressan, Célia L. L. F. Ferreira, and Maria C. G. Peluzio. 2013. "Higher Level of Faecal SCFA in Women Correlates with Metabolic Syndrome Risk Factors." *The British Journal of Nutrition* 109 (5): 914–19.
114. Thompson, L. R., J. G. Sanders, D. McDonald, and A. Amir. 2017. "A Communal Catalogue Reveals Earth's Multiscale Microbial Diversity." *Nature*. <https://www.nature.com/articles/nature24621?report=reader>.
115. Tseng, Ching-Hung, and Chun-Ying Wu. 2019. "The Gut Microbiome in Obesity." *Journal of the Formosan Medical Association = Taiwan Yi Zhi* 118 Suppl 1 (March): S3–9.
116. Turnbaugh, Peter J., Fredrik Bäckhed, Lucinda Fulton, and Jeffrey I. Gordon. 2008. "Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut Microbiome." *Cell Host & Microbe* 3 (4): 213–23.
117. Turnbaugh, Peter J., Micah Hamady, Tanya Yatsunencko, Brandi L. Cantarel, Alexis Duncan, Ruth E. Ley, Mitchell L. Sogin, et al. 2009. "A Core Gut Microbiome in Obese and Lean Twins." *Nature* 457 (7228): 480–84.
118. Turnbaugh, Peter J., Ruth E. Ley, Michael A. Mahowald, Vincent Magrini, Elaine R. Mardis, and Jeffrey I. Gordon. 2006. "An Obesity-Associated Gut Microbiome with Increased Capacity for Energy Harvest." *Nature* 444 (7122): 1027–31.


119. Valdes, Ana M., Jens Walter, Eran Segal, and Tim D. Spector. 2018. "Role of the Gut Microbiota in Nutrition and Health." *BMJ* 361 (June): k2179.
120. Vinolo, Marco A. R., Hosana G. Rodrigues, Renato T. Nachbar, and Rui Curi. 2011. "Regulation of Inflammation by Short Chain Fatty Acids." *Nutrients* 3 (10): 858–76.
121. Vrieze, Anne, Els Van Nood, Frits Holleman, Jarkko Salojärvi, Ruud S. Kootte, Joep F. W. M. Bartelsman, Geesje M. Dallinga-Thie, et al. 2012. "Transfer of Intestinal Microbiota from Lean Donors Increases Insulin Sensitivity in Individuals with Metabolic Syndrome." *Gastroenterology* 143 (4): 913-6.e7.
122. Walters, William, Embriette R. Hyde, Donna Berg-Lyons, Gail Ackermann, Greg Humphrey, Alma Parada, Jack A. Gilbert, et al. 2016. "Improved Bacterial 16S rRNA Gene (V4 and V4-5) and Fungal Internal Transcribed Spacer Marker Gene Primers for Microbial Community Surveys." *mSystems* 1 (1). <https://doi.org/10.1128/mSystems.00009-15>.
123. Wu, Gary D., Jun Chen, Christian Hoffmann, Kyle Bittinger, Ying-Yu Chen, Sue A. Keilbaugh, Meenakshi Bewtra, et al. 2011. "Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes." *Science* 334 (6052): 105–8.
124. Yan, Hang, Qian Qin, Jengfeng Chen, Su Yan, Tiantian Li, Xinxin Gao, Yang Yang, Ang Li, and Suying Ding. 2021. "Gut Microbiome Alterations in Patients With Visceral Obesity Based on Quantitative Computed Tomography." *Frontiers in Cellular and Infection Microbiology* 11: 823262.
125. Yang, Teng, Leho Tedersoo, Pamela S. Soltis, Douglas E. Soltis, Miao Sun, Yuying Ma, Yingying Ni, et al. 2022. "Plant and Fungal Species Interactions Differ between Aboveground and Belowground Habitats in Mountain Forests of Eastern China." *Science China. Life Sciences*, December. <https://doi.org/10.1007/s11427-022-2174-3>.
126. Yatsunencko, Tanya, Federico E. Rey, Mark J. Manary, Indi Trehan, Maria Gloria Dominguez-Bello, Monica Contreras, Magda Magris, et al. 2012. "Human Gut Microbiome Viewed across Age and Geography." *Nature* 486 (7402): 222–27.
127. Zhang, Qiang, Rong Zou, Min Guo, Mengmeng Duan, Quan Li, and Huajun Zheng. 2021. "Comparison of Gut Microbiota between Adults with Autism Spectrum Disorder and Obese Adults." *PeerJ* 9 (March): e10946.
128. Zhao, Liping. 2013. "The Gut Microbiota and Obesity: From Correlation to Causality." *Nature Reviews. Microbiology* 11 (9): 639–47.
129. Zhernakova, Alexandra, Alexander Kurilshikov, Marc Jan Bonder, Ettje F. Tigchelaar, Melanie Schirmer, Tommi Vatanen, Zlatan Mujagic, et al. 2016. "Population-Based Metagenomics Analysis Reveals Markers for Gut Microbiome Composition and Diversity." *Science* 352 (6285): 565–69.

## Table

**Table 1. METS-Microbiome participant characteristics from Ghana, South Africa, Jamaica, Seychelles and US. Data are presented as mean  $\pm$  standard deviation for continuous variables and percentages (%) for categorical variables.**

<b>Women</b>					
	<b>Ghana</b>	<b>South Africa</b>	<b>Jamaica</b>	<b>Seychelles</b>	<b>US</b>
	n=254	n=228	n=263	n=196	n=213
<i>Age (years)</i>	40.74 ± 8.1	35.56 ± 7.8	45.16 ± 7.5	43.84 ± 6.1	45.44 ± 6.4
<i>BMI (kg/m<sup>2</sup>)</i>	28.30 ± 5.9	33.42 ± 8.6	32.12 ± 7.3	30.32 ± 7.2	36.34 ± 8.8
<i>Obese (%)</i>	45,0%	61,0%	60,4%	49,5%	74,7%
<i>SBP (mm Hg)</i>	117.1 ± 18.5	115.20 ± 17.1	126.08 ± 19.0	123.28 ± 17.8	124.19 ± 18.4
<i>DBP (mm Hg)</i>	70.53 ± 12.2	75.20 ± 12.1	79.41 ± 12.6	79.37 ± 14.4	81.52 ± 12.1
<i>Hypertensive (%)</i>	37,5%	37,3%	57,4%	55,5%	65,4%
<i>Glucose (mg/dL)</i>	110.45 ± 62.7	89.17 ± 20.0	107.46 ± 39.1	111.35 ± 27.2	107.07 ± 44.0
<i>Diabetic (%)</i>	10,0%	3,5%	12,9%	13,9%	19,9%
<b>Men</b>					
	<b>Ghana</b>	<b>South Africa</b>	<b>Jamaica</b>	<b>Seychelles</b>	<b>US</b>
	n=117	n=171	n=133	n=164	n=107
<i>Age (years)</i>	43.92 ± 8.7	36.53 ± 7.2	44.42 ± 7.5	44.57 ± 5.1	47.12 ± 5.5
<i>BMI (kg/m<sup>2</sup>)</i>	23.7 ± 4.4	22.26 ± 4.1	24.8 ± 5.3	28.46 ± 5.5	30.37 ± 8.2
<i>Obese (%)</i>	13,4%	5,3%	15,7%	39,2%	44,4%
<i>SBP (mm Hg)</i>	121.28 ± 15.4	122.71 ± 15.5	129.23 ± 17.1	130.43 ± 16.2	130.67 ± 16.0
<i>DBP (mm Hg)</i>	68.02 ± 13.0	75.32 ± 11.1	78.07 ± 11.5	81.64 ± 12.1	82.37 ± 12.2
<i>Hypertensive (%)</i>	33,1%	45,0%	50,3%	65,9%	72,7%
<i>Glucose (mg/dL)</i>	100.52 ± 19.4	94 ± 23.4	99.04 ± 33.1	124.26 ± 44.2	107 ± 36.2
<i>Diabetic (%)</i>	4,6%	3,5%	4,8%	22,8%	17,5%


## Figures



**Figure 1**


**Variation in gut microbiome diversity.** (a) Alpha diversity estimated by Shannon, Observed ASVs and Faith's PD (Phylogenetic Diversity) between countries. (b) Alpha diversity estimated by Shannon, Observed ASVs and Faith's PD (Phylogenetic Diversity) between obese and non-obese. Alpha diversity metrics (Faith's PD, Observed ASVs and Shannon) are shown on the y-axis in different panels, while country or obese group are shown on the x-axis. (c) Beta diversity principal coordinate analysis based on

weighted UniFrac distance between countries. **(d)** Beta diversity principal coordinate analysis based on weighted UniFrac distance between obese and non-obese. **(e)** Beta diversity principal coordinate analysis based on unweighted UniFrac distance between countries. **(f)** Beta diversity principal coordinate analysis based on unweighted UniFrac distance between obese and non-obese. Proportion of variance explained by each principal coordinate axis is denoted in the corresponding axis label. **(g)** Venn diagram of shared and unique ASVs between the five countries. Box plots show the interquartile range (IQR), the horizontal lines show the median values, and the whiskers extend from the hinge no further than 1.5\*IQR. Each colored dot denotes a sample. Statistical significance adjusted for multiple comparisons using false discovery rate (FDR) correction are indicated: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; \*\*\*,  $P < 0.001$  across countries and obese groups (Kruskal-Wallis test) for alpha diversity or by permutational multivariate analysis of variance (PERMANOVA) for beta diversity. Alpha diversity analysis for country,  $n=1873$  samples (Ghana,  $n= 373$ ; South Africa,  $n=390$ ; Jamaica,  $n= 401$ ; Seychelles,  $n= 396$ ; USA,  $n= 313$ ) and obesity status,  $n=1764$  samples. For Beta diversity analysis,  $n=1764$  samples.




**Figure 2**

**Variation in gut microbiome composition.** Differentially abundant taxa among **(a)** countries and **(b)** obese group adjusted for BMI, age, sex and country using ANCOM-BC. Bars represent ANCOM-BC estimated log fold change between compared groups and error bars, with the 95% confidence interval. Representative ASVs with log fold change  $>1.4$  in at least one group are shown for country. FDR-adjusted ( $p < 0.05$ ) effect sizes are indicated by \*, \*\* and \*\*\*, corresponding to  $p < 0.05$ ,  $<0.01$  and  $<0.001$  respectively.  $n = 1694$  samples. FDR= False Discovery Rate.



**Figure 3**


**Receiver operating characteristic curves showing the classification accuracy of gut microbiota in a Random Forest model.** Classification accuracy for estimating (a). All countries (n=1694); (b) Obesity status (n=1694), (c). Diabetes status (n=1657); (d). Glucose status (n=1657); (e). Hypertensive status (1694); (f). Sex (n=1694) are presented. AUC= area under the curve



**Figure 4**



**Shannon index correlates positively with fecal short chain fatty acids.** Correlations between Shannon diversity (n = 1764) and concentrations (n=1704) of the different types of fecal short chain fatty acids (SCFAs) namely (a) total SCFA; (b) Acetate; (c) Butyrate; (d) Propionate; (e) Valerate among countries. Each colored dot represents a sample of specific country and the horizontal line on scatterplot denotes line of best fit.



**Figure 5**

**Associations of gut microbiota ASVs with concentrations of short chain fatty acids (SCFAs).** (a) Heatmap of Spearman's correlation between concentrations of SCFAs (n=) and top 30 differentially abundant ASVs (identified by ANCOM-BC) among countries. (b) Heatmap of Spearman's correlation between concentrations of SCFAs and differentially abundant ASVs (identified by ANCOM-BC) for obese. Correlations are identified by Spearman's rank correlation coefficient. Brick red squares indicate positive correlation, gray squares represent negative correlation and white squares are insignificant correlation. Mapping from FDR adjusted p values are denoted as: \*, \*\* and \*\*\*, corresponding to  $p < 0.05$ ,  $<0.01$  and  $<0.001$  respectively.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [METSMicrobiomeSourceData.xlsx](#)
- [METSMicrobiomeSupplementaryInformation.docx](#)